Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 37
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04958031 | A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy | ||
| NCT04136873 | A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia | ||
| NCT05404529 | To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function | ||
| NCT04760769 | Open-label Trial in Parkinson's Disease (PD) | ||
| NCT04686786 | An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures | ||
| NCT05245539 | Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia | ||
| NCT05443724 | A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia | ||
| NCT05965219 | A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants | ||
| NCT05610189 | Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease | ||
| NCT05915546 | The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants | ||
| NCT04457310 | A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia | ||
| NCT04592536 | A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects | ||
| NCT04542499 | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations | ||
| NCT05824143 | Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants | ||
| NCT05227703 | A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia | ||
| NCT05940402 | A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function | ||
| NCT05581823 | Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants | ||
| NCT06435923 | A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants | ||
| NCT04295642 | A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease | ||
| NCT05123079 | Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants | ||
| NCT05227690 | A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia | ||
| NCT04787302 | PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing | ||
| NCT06366243 | A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants | ||
| NCT04244175 | A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures | ||
| NCT05547542 | Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing | ||
| NCT05404542 | To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function | ||
| NCT05941442 | A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder | ||
| NCT05106309 | Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants | ||
| NCT04223193 | Flexible-Dose Trial in Early Parkinson's Disease (PD) | ||
| NCT05644977 | A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease | ||
| NCT05935033 | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine | ||
| NCT05138653 | A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants | ||
| NCT05933187 | A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants | ||
| NCT04241393 | An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects | ||
| NCT04201093 | Fixed-Dose Trial in Early Parkinson's Disease (PD) | ||
| NCT04232878 | A Single Ascending Dose Trial of CVL-936 in Healthy Subjects | ||
| NCT06301971 | A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants |
